Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

J
Jabado, Nada

McGill University
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Nada Jabado
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Nada Jabado
Favorite
Jacene, Heather

Dana-Farber Cancer Institute
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Heather Jacene
Favorite
Jackett, Louise

Peter MacCallum Cancer Centre
(P 151) MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS
Louise Jackett
Favorite
Jadhav, Priyanka

University of California, San Diego
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Priyanka Jadhav
Favorite
Jagodzińska-Mucha, Paulina

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Paulina Jagodzińska-Mucha
Favorite
Jagosky, Megan

Levine Cancer Institute
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Megan Jagosky
Favorite
Janeway, Katherine

Department of Pediatrics, Dana-Farber / Boston Children’s Cancer and Blood Disorders Center Harvard Medical School
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Katherine Janeway
Favorite
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Katherine Janeway
Favorite
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Katherine Janeway
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Katherine Janeway
Favorite
Jansen, Katrien

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Katrien Jansen
Favorite
Jansen, Yanina

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Yanina Jansen
Favorite
Jansma, Christianne

Erasmus Medical Center and UMC Utrecht
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Christianne Jansma
Favorite
Jarutat, Tiantom

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Tiantom Jarutat
Favorite
Jawhar, Wajih

Research Institute of the McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Wajih Jawhar
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Wajih Jawhar
Favorite
Jean-Denis, Myriam

Department of Biopathology, CLCC Léon Bérard, Lyon University, Lyon, France & CRCL, University Claude Bernard Lyon 1, Lyon, France
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Myriam Jean-Denis
Favorite
Jee, Yeseob

Dankook University College of Medicine, Cheonan, Chungnam, Korea
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Yeseob Jee
Favorite
Jeffrey, Samantha

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Samantha Jeffrey
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Samantha Jeffrey
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Samantha Jeffrey
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Samantha Jeffrey
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Samantha Jeffrey
Favorite
Jennische, Eva

University of Gothenburg, Department of Medical Biochemistry and Cell Biology
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Eva Jennische
Favorite
Jensen, Michael

BrainChild Bio
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Michael Jensen
Favorite
Jesus-Garcia, Reynaldo

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Reynaldo Jesus-Garcia
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Reynaldo Jesus-Garcia
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Reynaldo Jesus-Garcia
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Reynaldo Jesus-Garcia
Favorite
Jiang, Yafei

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Yafei Jiang
Favorite
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Yafei Jiang
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Yafei Jiang
Favorite
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Yafei Jiang
Favorite
Jimenez, Marta

Unicancer
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Marta Jimenez
Favorite
Jin, Chunsheng

University of Gothenburg, Department of Medical Biochemistry and Cell Biology
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Chunsheng Jin
Favorite
Jin, Guangxu

Wake Forest
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Guangxu Jin
Favorite
Jing, Weiqing

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Weiqing Jing
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Weiqing Jing
Favorite
Jin, JinJi

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
JinJi Jin
Favorite
Johnson, Daniel

Vanderbilt University Medical Center
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Daniel Johnson
Favorite
Johnson, Shavaughn

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Shavaughn Johnson
Favorite
Johnson, Shelby

Medical Research Scholars Program (MRSP), National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Shelby Johnson
Favorite
Johnstone, Sarah

Dana-Farber Cancer Institute
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Sarah Johnstone
Favorite
Jolivet, Philippe

McGill University
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Philippe Jolivet
Favorite
Jonczak, Emily

University of Miami, Sylvester Comprehensive Cancer Center
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Emily Jonczak
Favorite
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Emily Jonczak
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Emily Jonczak
Favorite
Jonczak, Emily

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Emily Jonczak
Favorite
Jonczak, Emily

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Emily Jonczak
Favorite
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Emily Jonczak
Favorite
Jones, Conor

Rush University Medical Center
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Conor Jones
Favorite
Jones, Emily

National Disease Registration Service, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Emily Jones
Favorite
Jones, Kevin

Department of Orthopaedics, University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Kevin Jones
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Kevin Jones
Favorite
Jones, Paul

Washington University
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Paul Jones
Favorite
Jones, Robin

Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Robin Jones
Favorite
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Robin Jones
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Robin Jones
Favorite
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Robin Jones
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Robin Jones
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Robin Jones
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Robin Jones
Favorite
Joo, Min Wook

The Catholic University of Korea
(P 218) SEX DIFFERENCES IN THE ASSOCIATION OF ALCOHOL INTAKE WITH THE RISK OF SOFT-TISSUE SARCOMA: A NATIONWIDE POPULATION-BASED RETROSPECTIVE COHORT STUDY
Min Wook Joo
Favorite
Joyce, David

Moffitt Cancer Center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
David Joyce
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
David Joyce
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
David Joyce
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
David Joyce
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
David Joyce
Favorite
Joyce, Molly

Oregon Health & Science University
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Molly Joyce
Favorite
Jude Michael, Michelle

Princess Margaret Cancer Center
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Michelle Jude Michael
Favorite
Judge, Charlotte

National Disease Registration Service, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Charlotte Judge
Favorite
Judge, Sean

Department of Surgery, Memorial Sloan Kettering Cancer Center
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Sean Judge
Favorite
Jung, Wonkyung

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Wonkyung Jung
Favorite
Junker, Niels

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Niels Junker
Favorite
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Niels Junker
Favorite
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Niels Junker
Favorite
Just, Marissa

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Marissa Just
Favorite
Jutte, Paul

University Medical Center Groningen
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Paul Jutte
Favorite
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Paul Jutte
Favorite